Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta(R) in healthy subjects: A randomized, double-blind trial

Wynne, C; Schwabe, C; Vincent, E; Schueler, A; Ryding, J; Ullmann, M; Ghori, V; Kanceva, R; Stahl, M

Stahl, M (corresponding author), Fresenius Kabi SwissBioSim GmbH, Terre Bonne Business Pk,Route Crassier 23, CH-1262 Eysins, Switzerland.

PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020; 8 (2):

Abstract

MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta(R)). This study was designed primarily to compare the im......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索